Jana Reynolds is an Oncology physician affiliated with Baylor University Medical Center. OpenAlex indexes 17 publications with 226 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3410 Worth St Ste 300
Dallas, TX 752462012
Telephone
214-370-1500Registry record last updated 3 May 2017.
Industry payments
33 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20252 payments
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
72.7%Human Immunoglobulin G70.8%Immune globulin100%Part B, office-administered≥18 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor1.9%Valacyclovir100%Part D≥12 patientsSensory organs
12.7%Corticosteroid12.7%Dexamethasone sodium phosphate95%Dexamethasone5%Part D + Part B<11 patientsCancer & immunology
3.8%Kinase inhibitor2.3%Jakafi100%Part D≥11 patientsThalidomide Analog0.9%Pomalyst67%Revlimid33%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Parkinsonism Post BCMA-Directed CAR-T Therapy in Multiple Myeloma Patients: A Real-World Analysis
Biology of Blood and Marrow Transplantation
2026 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
Biology of Blood and Marrow Transplantation
2023 - Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation
2022 - Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors
Biology of Blood and Marrow Transplantation
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Grayburn, MD
Baylor University Medical Center
Stuart Spechler, MD
Baylor University Medical Center
Brooks Cash, MD
Baylor University Medical Center
Robert Perrillo, MD
Baylor University Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”